Finance

Lists
Q3 2026 earnings • released • EPS beat +8.62% • Revenue beat +2.31%
See results
EW:NYSE
Edwards Lifesciences Corp
US$100.82
+1.46%
(+1.45) 1D
US$100.00
-0.81% (-0.82)
After hours
Closed: ኖቬም 5, 4:00:05 ከሰዓት ጂ ኤም ቲ-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EW...
Open
US$100.67
High
US$104.16
Low
US$98.77
Mkt. cap
58.11 ቢ
Avg. vol.
4.14 ሚ
Volume
9.23 ሚ
P/E ratio
58.33
52-wk high
US$104.16
52-wk low
US$74.66
EPS
US$1.73
Beta
0.85
Shares outstanding
576.40 ሚ
No. of employees
16 ሺ
Open
US$100.67
High
US$104.16
Low
US$98.77
Mkt. cap
58.11 ቢ
Avg. vol.
4.14 ሚ
Volume
9.23 ሚ
P/E ratio
58.33
52-wk high
US$104.16
52-wk low
US$74.66
EPS
US$1.73
Beta
0.85
Shares outstanding
576.40 ሚ
No. of employees
16 ሺ
News stories
From web sources and news partners
Profile
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027. Wikipedia
About Edwards Lifesciences Corp
CEO-
Employees16 ሺ
Founded1958
Headquartersኢርቪን, ካሊፎርኒያ, ዩናይትድ ስቴትስ
SectorHealth Care
IndustryMedical device
Websiteedwards.com
Analyst ratings
Based on 23 analysts giving stock ratings to EW in the past 3 months
Strong buy
Buy
20
Hold
3
Sell
0
12-month forecast
Based on 23 Wall Street analysts offering 12 month price targets for EW in the last 3 months.
Highest
Current US$100.82
US$125.00 (+23.98%)
Average
US$114.30 (+13.37%)
Lowest
US$97.00 (-3.79%)
Analyst
Recommendation
Action
Price target
Projected
Date
Travis Steed
Bank of America Securities
Buy
Maintained
-
-
11/05/2026
Mike Kratky
Leerink Partners
Buy
Reiterated
US$112.00
+11.1%
11/05/2026
Anthony Petrone
Mizuho Securities
Buy
Maintained
US$120.00
+19%
11/05/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
US$112.00
+11.1%
11/05/2026
David Rescott
Robert W. Baird
Buy
Upgraded
US$116.00
+15.1%
11/05/2026
David Roman
Goldman Sachs
Buy
Maintained
US$115.00
+14.1%
11/05/2026
Kendall Au
RBC Capital
Buy
Reiterated
US$115.00
+14.1%
11/05/2026
Shagun Singh Chadha
RBC Capital
Buy
Reiterated
US$115.00
+14.1%
11/05/2026
Rick Wise
Stifel Nicolaus
Buy
Maintained
US$120.00
+19%
11/05/2026
Adam Maeder
Piper Sandler
Buy
Reiterated
US$115.00
+14.1%
11/05/2026
Robbie Marcus
J.P. Morgan
Buy
Maintained
US$120.00
+19%
11/05/2026
Patrick Wood
UBS
Buy
Reiterated
US$118.00
+17%
11/05/2026
Lee Hambright
Bernstein
Hold
Maintained
US$106.00
+5.1%
11/05/2026
Larry Biegelsen
Wells Fargo
Buy
Reiterated
US$113.00
+12.1%
11/05/2026
Joanne Wuensch
Citi
Buy
Reiterated
US$117.00
+16%
11/05/2026
Nico Chen
DBS
Buy
Maintained
US$125.00
+24%
11/05/2026
Unknown Analyst
Oppenheimer
Hold
Maintained
-
-
11/05/2026
William Plovanic
Canaccord Genuity
Hold
Maintained
US$97.00
-3.8%
11/05/2026
Christopher Pasquale
Barclays
Buy
Maintained
US$120.00
+19%
11/05/2026
Richard Newitter
Truist Financial
Buy
Upgraded
US$113.00
+12.1%
11/03/2026
Chris Krueger CFA
TD Cowen
Buy
Reiterated
US$117.00
+16%
11/05/2026
Josh Jennings
TD Cowen
Buy
Reiterated
US$117.00
+16%
11/03/2026
Marie Thibault
BTIG
Buy
Reiterated
US$110.00
+9.1%
10/09/2026
Matt Miksic
Barclays
Buy
Maintained
US$110.00
+9.1%
10/07/2026
Tycho Peterson
Jefferies
Buy
Initiated
US$110.00
+9.1%
10/07/2026
Matthew Taylor
Jefferies
Buy
Maintained
US$105.00
+4.1%
09/11/2026
Brandon Vazquez
William Blair
Buy
Maintained
-
-
09/10/2026
Suraj Kalia
Oppenheimer
Hold
Maintained
-
-
07/24/2026
Krish Sankar
TD Cowen
Buy
Reiterated
US$104.00
+3.2%
06/02/2026
David Toung
Argus Research
Buy
Maintained
-
-
05/21/2026
Michael Polark
Wolfe Research
Buy
Upgraded
US$92.00
-8.7%
04/01/2026
Danielle Antalffy
UBS
Hold
Maintained
US$90.00
-10.7%
02/12/2026
Last report
5 ኖቬም 2026
Fiscal period
Q3 2026
US$0.80 / US$0.74
+8.62%beat
Revenue / Est. (USD)
1.72 ቢ / 1.68 ቢ
+2.31%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ሴፕቴ 2025
ዲሴም 2025
ማርች 2026
ጁን 2026
Revenue
1.55 ቢ
1.57 ቢ
1.65 ቢ
1.74 ቢ
Cost of goods sold
345.20 ሚ
343.00 ሚ
362.60 ሚ
392.40 ሚ
Cost of revenue
345.20 ሚ
343.00 ሚ
362.60 ሚ
392.40 ሚ
Research and development expenses
280.70 ሚ
267.70 ሚ
263.30 ሚ
278.90 ሚ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
514.60 ሚ
601.20 ሚ
522.20 ሚ
561.20 ሚ
Operating expense
782.80 ሚ
854.60 ሚ
771.30 ሚ
829.10 ሚ
Total operating expenses
1.13 ቢ
1.20 ቢ
1.13 ቢ
1.22 ቢ
Operating income
425.10 ሚ
372.00 ሚ
514.70 ሚ
519.50 ሚ
Other non operating income
1.10 ሚ
2.30 ሚ
69.90 ሚ
-25.00 ሚ
EBT including unusual items
348.40 ሚ
90.40 ሚ
459.00 ሚ
519.80 ሚ
EBT excluding unusual items
444.50 ሚ
464.00 ሚ
603.60 ሚ
511.10 ሚ
Income tax expense
56.10 ሚ
26.20 ሚ
78.30 ሚ
278.40 ሚ
Effective tax rate
16.10%
28.98%
17.06%
53.56%
Other operating expenses
-12.50 ሚ
-14.30 ሚ
-14.20 ሚ
-11.00 ሚ
Net income
291.10 ሚ
91.20 ሚ
380.70 ሚ
241.90 ሚ
Net profit margin
18.74%
5.81%
23.09%
13.89%
Earnings per share
0.67
0.58
0.78
0.78
Interest and investment income
16.70 ሚ
114.20 ሚ
17.40 ሚ
15.00 ሚ
Interest expense
-
-20.40 ሚ
-
-
Net interest expenses
16.70 ሚ
93.80 ሚ
17.40 ሚ
15.00 ሚ
Depreciation and amortization charges
-
-
-
-
EBITDA
464.30 ሚ
414.70 ሚ
555.60 ሚ
562.20 ሚ
Gain or loss from assets sale
-
-33.90 ሚ
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google መተግበሪያዎች